S
CHRS icon

SignatureFD’s Coherus Oncology CHRS Stock Holding History

SignatureFD’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-143
Closed -$611 – 3212
2023
Q2 		$611 Buy
143
+38
+36% +$224 ﹤0.01% 3051
2023
Q1 		$718 Hold
105
– – ﹤0.01% 3046
2022
Q4 		$832 Sell
105
-53
-34% -$408 ﹤0.01% 3008
2022
Q3 		$2K Buy
158
+22
+16% +$223 ﹤0.01% 2740
2022
Q2 		$1K Buy
136
+55
+68% +$478 ﹤0.01% 2885
2022
Q1 		$1K Buy
+81
New +$1.03K ﹤0.01% 2958
2021
Q4 		– Sell
-45
Closed -$1K – 3130
2021
Q3 		$1K Buy
+45
New +$660 ﹤0.01% 2793
2021
Q2 		– Sell
-80
Closed -$1K – 2957
2021
Q1 		$1K Buy
+80
New +$1.36K ﹤0.01% 2600
2018
Q4 		– Sell
-5
Closed – – 1951
2018
Q3 		$0 Hold
5
– – ﹤0.01% 1915
2018
Q2 		$0 Hold
5
– – ﹤0.01% 1915
2018
Q1 		$0 Buy
+5
New +$55 ﹤0.01% 1741

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

SignatureFD's CHRS Position: Q3 2023 in Review

SignatureFD sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 143 shares — an estimated $611 sold.

SignatureFD first reported a position in CHRS in Q1 2018 and held it in 11 quarters. The position peaked at $2K in Q3 2022. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • SignatureFD reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • SignatureFD sold 143 Coherus Oncology shares in Q3 2023, an estimated $611.
  • SignatureFD first reported a position in Coherus Oncology in Q1 2018 and held it in 11 quarters.
  • SignatureFD's Coherus Oncology position peaked at $2K in Q3 2022.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on SignatureFD's 13F filing for Q3 2023, filed 3 Nov 2023.